A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)

Study Identifier
P16-326
CT.gov Identifier
NCT03505892
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Axial Spondyloarthritis (axSpA)
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Participants with confirmed AS. * Participant will start adalimumab as treatment * Participant must provide the written authorization form and agree to provide personal and/or health data prior to the entry into the study.
    Exclusion Criteria:
    * Participant has been treated with any investigational drug or biologic within a minimum of 30 days or five half-lives (whichever is longer) of the drug prior to the Baseline Visit. * Participants who fulfill any of the contraindications as per Humira label in Taiwan.

    Protocol Summary

    The objectives of this prospective observational study is to explore 1-year clinical response via both Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) after initiation of adalimumab therapy in AS patients from routine clinical practices in Taiwan.

    Study Locations

    Location
    Status
    Location
    Hualien Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation
    Hualien City, Taiwan, 970
    Status
    Not applicable